ABSTRACr Beta adrenergic agents given by aerosol decrease the responsiveness of the airways to histamine and methacholine in subjects with asthma, causing a shift of the dose response curve to the right. To find out whether the shift is related to the dose of beta adrenergic agent given and to determine the duration of the reduced responsiveness, eight subjects with asthma were given histamine inhalation tests after inhaled saline and after increasing doses of inhaled fenoterol on different days. The histamine inhalation tests were repeated at hourly intervals for five hours after a selected dose of fenoterol. Fenoterol caused a dose related shift to the right of the histamine dose response curve in each subject and in some the dose response relationship reached the "non-symptomatic range. The shift in the dose response curve was short lived and had returned towards the control position within three hours in all subjects. There was no change in shape of the curves at the time of maximal shift. The results show that inhaled fenoterol greatly reduces the airway responsiveness to histamine, but up to 400 ,ug of fenoterol every four to five hours may be needed to keep the responsiveness of the airways in the non-symptomatic range. Dose response curves showing the response of the airways to inhaled histamine can be plotted from the results of carefully conducted bronchial provocation tests. The airway response to inhaled histamine is much greater in asthmatic than in non-asthmatic subjects. The factors responsible for this increased responsiveness are not known. It is, however, known that the position of the dose response curve, based on the dose which causes a 20% fall in the one second forced expiratory volume (PD2oFEv,), varies with the severity of the disease and is shifted to the left (increased responsiveness) by exacerbations of asthma and by allergen challenge.' 2 We have shown that inhaled fenoterol greatly decreases the responsiveness to histamine in asthmatic subjects, shifting the dose response curve to the right.3
Dose response curves showing the response of the airways to inhaled histamine can be plotted from the results of carefully conducted bronchial provocation tests. The airway response to inhaled histamine is much greater in asthmatic than in non-asthmatic subjects. The factors responsible for this increased responsiveness are not known. It is, however, known that the position of the dose response curve, based on the dose which causes a 20% fall in the one second forced expiratory volume (PD2oFEv, ), varies with the severity of the disease and is shifted to the left (increased responsiveness) by exacerbations of asthma and by allergen challenge.' 2 We have shown that inhaled fenoterol greatly decreases the responsiveness to histamine in asthmatic subjects, shifting the dose response curve to the right.3
This study was undertaken to determine whether the histamine dose response curve is shifted in a dose related manner after inhaled fenoterol, how long the reduced responsiveness lasts, and whether prior inhalation of fenoterol changes the shape of the dose response curve.
Effect ofaerosol fenoterol on the severity of bronchial hyperreactivity in patients with asthma 
PROTOCOL
On the first day a standard challenge, as described above, was performed. On the second day, after spirometry, 100 ,ug fenoterol was inhaled from the nebuliser. This was given as four inhalations from FRC to TLC taking five to six seconds, with the breath held for 20 seconds at TLC. FEV1 was measured 20 minutes later, after which a histamine challenge was given as on day 1. This procedure was repeated on the third and fourth days after 200 and 400 ,ug fenoterol respectively.
On the fifth day 400 ,ug fenoterol was given to five subjects, 200 ,ug to one, and 100 ,g to the other two. The histamine challenge was repeated hourly for five hours. In all subjects the dose of fenoterol selected was the dose that moved the response curve to a range not usually associated with symptoms of asthma.6 The aim of this part of the study was to determine the effective duration of a dose necessary to make each subject symptom free.
The dose of histamine, recorded in terms of micromoles delivered by the nebuliser to the mouth of the subject, was plotted on a log scale against percentage fall in FEV, from the post-saline (day 1) or post-fenoterol (days [2] [3] [4] [5] Each dose of fenoterol resulted in a significant increase in FEV, (p < 0-001), though the mean percentage increase was not significantly different after 100, 200, and 400 ,tg fenoterol. Mean FEV, after 400 ,ug was 98% of the predicted value, a 14% increase, compared with 92% after 100 ug, an 1 1% increase. Figure 1 shows the dose response curves after each dose of fenoterol and at hourly intervals after 400 ug in two representative subjects. In both subjects 400 ,ug fenoterol increased PD2O-FEv, roughly 100 fold. Table 2 shows the effect of time on the response to fenoterol. The FEV, (% predicted) before each hourly challenge and PD2o-FEvI values for each challenge are shown. After fenoterol, mean FEV, increased from 82% (SD 18%) to 97% (16%) (p < 0-001). At 15 minutes the PD2o-FEVy had increased to more than 1-0 ,tmol in all subjects and to more than 4-0 ,umol in four. Values remained above the baseline for five hours in six subjects and for four hours in two, although the dose response curve showed roughly a 10 fold change for only two to three hours. The PD2o-FEvi returned towards control values much more rapidly than the FEV,, which was well maintained at four hours in most subjects. This can be seen in figure 2 , which shows the relationship between PD20-FEV, and the FEV, at the time of challenge for three typical subjects.
Values for a, 83, and r (correlation coefficient) are (fig 2) .
The reason for this difference between bronchodilating and protective effects is not apparent. Possibly fenoterol stops histamine getting in to the submucosa or has two different actions at the smooth muscle level. It is known that inhaled beta2 agonist drugs protect against methacholine, exercise, and allergen challenges. This suggests that the asthmatic subject is dependent on the beta2 receptor for protection against various sources of provocation. Salome, Schoeffel, Yan, Woolcock The degree to which the dose response curve was shifted was not related to the position of the curve on the control day. Subjects 2 and 3, who had very different control values for PD2o-FEvi (0.095 and 1-8 ,umol), both shifted to more than 11 umol-well within the "non-symptomatic" range.
There are practical implications for treatment suggested by this study. Firstly, if the dose response curve is to be kept in the non-symptomatic range it may well be necessary to give fenoterol every four hours. Secondly some people will be relatively free from symptoms while taking fenoterol, regardless of the current FEVp, whereas others, like subjects 5, 6, 7, and 8, will not. In these subjects the PD2o-FEVI was back in the symptomatic range within two hours of inhaling fenoterol. 
